Ashvattha Therapeutics – Developing a New Class of Intracellular Targeted Therapeutics
We have designed a potent anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye
3 members
